Browsing by Author "Soyoral, Yasemin"

Now showing 1 - 16 of 16

Burkitt Lymphoma in Renal Transplant Recipient
(Taylor & Francis inc, 2007) Soyoral, Yasemin; Dogan, Ekrem; Sayarfloglu, Hayriye; Erkoc, Reha; Begenik, Huseyin
Cloudy Dialysate Due To Lercanidipine
(Oxford Univ Press, 2006) Topal, Cevat; Sayarlioglu, Hayriye; Dogan, Ekrem; Erkoc, Reha; Soyoral, Yasemin
Coexistence of Chronic Renal Failure, Hashimoto Thyroiditis and Idiopathic Hypoparathyroidism: a Rare Case Report
(informa Healthcare, 2014) Yildiz, Saliha; Soyoral, Yasemin; Demirkiran, Davut; Ozturk, Mustafa
Hypoparathyroidism is an uncommon disease and its coexistence with chronic renal failure is quite rare. Hypocalcemia and hyperphosphatemia are seen in both diseases. Diagnosis of hypoparathyroidism may be overlooked when parathormone response is not evaluated in patients with chronic renal failure. A 19-year-old female patient who had been receiving hemodialysis for 3 years because of chronic renal failure was diagnosed as idiopathic hypoparathyroidism and hashimoto thyroiditis. When her medical records on the first admission and medical history were evaluated, hypoparathyroidism and hashimoto thyroiditis were seen to be present also when she was started hemodialysis. Idiopathic hypoparathyroidism should be suspected in case as absence of parathormone response to hypocalcemia in patients with chronic renal failure. It should be taken into consideration that hashimoto thyroiditis may accompany and required analysis should be done.
Diurnal Rhythm of Urinary Calcium Excretion in Adults
(Taylor & Francis inc, 2008) Topal, Cevat; Algun, Ekrem; Sayarlioglu, Hayriye; Erkoc, Reha; Soyoral, Yasemin; Dogan, Ekrem; Cekici, Saliha
Twenty-four-hour urinary calcium excretion is normally the equivalent of daily calcium intake, and varies between 200-300 mg/dL with a calcium/creatinine ratio of 0.07-0.15. In this study, we aimed to investigate the diurnal rhythm of calcium excretion in healthy individual. Forty subjects (30 male, 10 female) were involved into the study. The spot urine samples were taken at 08: 00, 14: 00, and 22: 00 together with a 24-hour collection. Mean spot urinary calcium levels at 08: 00, 14: 00, and 22: 00 were 12.39 +/- 8.19, 12.97 +/- 8.37, and 16.95 +/- 10.39 mg/dL, with calcium/creatinine ratios of 0.104 +/- 5.261, 0.119 +/- 7.85, and 0.133 +/- 8.17, respectively. Twenty-four-hour urinary calcium excretion was 12.74 +/- 7.31 mg/dL with a calcium/creatinine ratio of 0.111 +/- 5.41. The values at 08: 00, 14: 00, and of 24-hour collection were statistically similar (p > 0.05), but the nighttime values were significantly elevated (p < 0.05). In conclusion, calcium excretion is increased at night, and urinary calcium measurements should be interpreted accordingly.
Effect of Depot Oral Cholecalciferol Treatment on Secondary Hyperparathyroidism in Stage 3 and Stage 4 Chronic Kidney Diseases Patients
(Taylor & Francis Ltd, 2008) Dogan, Ekrem; Erkoc, Reha; Sayarlioglu, Hayriye; Soyoral, Yasemin; Dulger, Haluk
By the time patients require dialysis replacement therapy, nearly all chronic kidney diseases (CKD) patients are affected with uremic bone diseases. High-turnover osteodystrophy can be prevented; patients with CKD should be monitored for imbalances in calcidiol (25 OH vitamin D), calcium, and phosphate homeostasis. We aimed to determine the effect of a monthly oral 300,000 IU vitamin D-3 (cholecalciferol) supplementation on the uremic bone diseases (UBD) markers such as iPTH and alkaline phosphatase in CKD patients. Among a total of 70 patients under treatment in the nephrology unit, 40 predialysis CKD patients (mean age of 49 14, male/female 20/20) were included the study. The patients were randomly divided into two groups. Treatment group included 20 patients (mean age of 51 +/- 14, male/female 9/11), and the control group comprised 20 patients (mean age of 47 +/- 14, male/female 9/11). Treatment group patients were given a single dose of Devit3 ampoule (300,000 U cholecalciferol) per month orally way. Patients in the control group did not take any vitamin D for a month. The level of calcidiol was lower than normal range in two groups. After a month, treatment group patient's calcidiol increased statistically significant (6.8 +/- 3.5 to 17.8 +/- 21.4 ng/mL, p < 0.001). After a month, iPTH level decreased in the treatment group statistically significantly (368 +/- 274 to 279 +/- 179 pg/ml, p < 0.001). At the 30(th) day of the treatment, in 9/20 of the treatment group patients (45%), the iPTH value decreased at least 30% (p < 0.001). We suggest that oral depot cholecalciferol treatment causes a statistically significant decrease of serum iPTH level but does not cause a statistically significant change in Ca, P, ratio of CaxP, or urinary calcium creatinine rate in UBD predialysis CKD. This treatment can be used safely for the predialysis CKD patients, along with the cautious control of serum calcium and phosphor.
The Effect of Zofenopril on the Peritoneal Membrane in Capd Patients
(Oxford Univ Press, 2006) Sayarlioglu, Hayriye; Dogan, Ekrem; Erkoc, Reha; Soyoral, Yasemin; Kara, Pinar; Baykal, Sanem; Guducuoglu, Huseyin
Effects of Low Sodium Dialysate in Chronic Hemodialysis Patients With Hypertension
(Oxford Univ Press, 2007) Esen, Ramazan; Erkoc, Reha; Sayarlioglu, Hayriye; Soyoral, Yasemin; Dogan, Ekrem; Sekeroglu, Ramazan; Begenik, Huseyin
Effects of Low Sodium Dialysate in Chronic Hemodialysis Patients: an Echocardiographic Study
(Taylor & Francis Ltd, 2007) Sayarlioglu, Hayriye; Erkoc, Reha; Tuncer, Mustafa; Soyoral, Yasemin; Esen, Ramazan; Gumrukcuoglu, Hasan Ali; Sayarlioglu, Mehmet
Background. Chronic kidney disease (CKD) and hemodialysis (HD) patients who cannot restrict sodium consumption in their diets sometimes develop significant saline excess and hypertension between dialyses. This study assessed the effect of relatively low sodium dialysate dialysis on changes of echocardiography in hemodialysis patients. Methods and Results. Eighteen patients with end stage renal failure on chronic HD were studied (8 females, 10 males) with a mean age 48.3 +/- 14.6 (24-70) years. The mean time on HD was 30.8 +/- 14.0 (12-60) months. Patients with hematocrit levels under 24% were excluded from the study. In all patients, echocardiography was performed thrice weekly before and after eight-week HD treatment with low sodium dialysate hemodialysis by the same operator (135 mEq/L for patients with sodium levels less than 137, 137 for patients with sodium levels over 137). Left atrium (LA) and left ventricle (LV) volumes and ejection fractions were measured, specifically: LV systolic diameter (LVSD), LV diastolic diameter (LVDD), interventricular septum (IVS), tricuspid regurgitation (TR), mitral regurgitation (MR), pulmonary artery pressure (PAP), and inferior vein cava diameter (IVCD). Results. In terms of echocardiographic parameters, LVSD, TR, PAP, and IVCD were statistically decreased after low-sodium dialysate treatments (p = 0.002, 0.04, 0.013, and 0.00, respectively). Predialysis systolic and diastolic blood pressure (BP), post-dialysis systolic blood pressure, and interdialytic weight gain was statistically decreased when compared to basal levels (p = 0.00, p = 0.011, p = 0.022, p = 0.001, respectively). Conclusion A reduction of the dialysate sodium concentration based on the predialysis sodium levels of the patients could reduce the systolic BP and decrease the volume load on the heart as assessed by echocardiography. Within this short period, postdialysis diastolic BP could not be lowered. The effect of this approach should be studied in broad and lengthy series.
Gall Bladder Perforation, a Rare Complication of Continuous Ambulatory Peritoneal Dialysis: Case Report
(Turk Nefroloji Diyaliz Transplantasyon dergisi, 2007) Sayarlioglu, Hayriye; Soyoral, Yasemin; Dogan, Ekrem; Kotan, Cetin; Asian, Murat; Baser, Murat; Erkoc, Reha
Continuous ambulatory peritoneal dialysis (CAPI2b is a widely used method al the treatment of end stage Fero' failure patients, Mechanical and meoholo cornplications can be detected during CAPD treatment. Perforwions of inusanderpinal organs are rarely seen complitations CAR) benefits We presented a CAPD patient anth gall bladder perfuranan.
Life-Threatening Hypophosphatemia And/Or Phosphate Depletion in a Patient With Acute Lymphoblastic Leukemia: a Rare Case Report
(W B Saunders Co-elsevier inc, 2014) Soyoral, Yasemin; Aslan, Mehmet; Ebinc, Senar; Dirik, Yaren; Demir, Cengiz
Acute severe hypophosphatemia can be life threatening and is associated with mortality and impaired cardiac and respiratory function. Several conditions including decreased absorption or increased urinary phosphate excretion, shifts from the extracellular to intracellular compartments, and phosphate consumption by rapidly proliferating cells are known to induce moderate to severe acute hypophosphatemia. Although hypophosphatemia and/or phosphate depletion in patients with acute or chronic myeloid leukemia have been reported in the literature, hypophosphatemia due to acute lymphoblastic leukemia (ALL) is very rare. We report a case of history of ALL complicated by life-threatening hypophosphatemia manifesting as generalized muscle weakness, fatigue, acute shortness of breath, and difficulty in standing up and walking for 3 days. Serum inorganic phosphate levels were consistently low (0.06 mmol/L). The patient was hospitalized and thought to have a relapsed ALL. Anticancer agents and oral phosphate (660 mg twice daily) were administered. On the second day of treatment, the patient began to improve, and the patient gradually fully recovered within 5 days. We suggested that this hypophosphatemia was induced by a shift of phosphorus into leukemic cells that rapidly replicated in the tissues and excessive cellular phosphate consumption by rapidly proliferating cells. Serum phosphate levels should always be monitored, especially in suspected life-threatening manifestation in relapsed ALL.
Lymphocyte Subtype and Immunglobulins Levels in Hcv Positive Hemodialysis Pateints
(Modestum Ltd, 2012) Sayarlioglu, Hayriye; Erkoc, Reha; Dogan, Ekrem; Soyoral, Yasemin; Oner, Ahmet Faik
Epidemiological studies indicate that in chronic HD patients, bacterial and viral infection rank second place in mortality and morbidity, behind cardiovascular disease. Chronic hepatitis C virus (HCV) is very prevalent in some Hemodialysis (HD) centers. We have investigated lymphocyte subtype count and immunoglobulin levels in hemodialyzed patient with HCV. We studied 55 patients with end stage renal disease (ESRD) on chronic HD and 21 healty subjects. Patients group included 34 female and 21 male with mean age 46.5 +/- 16.1(18-77) years. Serum concentrations of IgG, IgM, IgA, CD4, CD8, CD19, CD16-56 lymphocytes were measured. Kt/V values were calculated according to DOQI guideline. Lymphocyte and lymphocyte subgroups values of HD patients were significant lower than healty persons. IgG, IgM and ALT levels of HCV positive HD patients compared with significant higher than HCV negative HD patients. CD4/CD8 ratios within groups were no differences. Lymphocyte subtype count of between HCV positive and HCV negative HD patients was no differences. IgG and IgM levels of HCV positive HD patients were higher than HCV negative HD patients. High Ig levels were also associated with ALT levels
Prevalence and Risk Factors of Restless Leg Syndrome in a Single Hemodialysis Unit
(Tubitak Scientific & Technological Research Council Turkey, 2010) Soyoral, Yasemin; Sayarlioglu, Hayriye; Tuncel, Deniz; Sahin, Murat; Dogan, Ekrem; Erkoc, Reha
Aim: Restless legs syndrome (RLS) is characterized by symptoms of spontaneous, continuous leg movements associated with unpleasant paresthesias. RLS is common among dialysis patients, with a reported incidence of 6 6 to 6 8 percent. This study is an attempt to find out the prevalence of RLS in our hemodialysis patients. We compared several demographic and clinical characteristics of RLS patients identified by the International Restless Legs Syndrome Study Group (IRLSSG) criteria with those of individuals without RLS. Materials and methods: We studied 76 patients with end-stage renal disease (ESRD) on hemodialysis (34 females and 42 males, mean age 52 28 +/- 18.13, range 18-83 years) RLS patients' diagnoses were confirmed using the IRLSSG criteria. RLS is diagnosed when a patient answered positively to all of the 4 questions. Hemoglobin, ferritin, iron, iron binding capacity, PTH, and Kt/V ratio values were measured Results: We found an RLS frequency of 14 5% in our sample. There was no significant difference in terms of serum iron, terrain, creatinine, iPTH, hemoglobin, and Kt/V between groups of hemodialysis patients with and without RLS (P = 0.89, 0 87, and 0 37, respectively) Conclusion: The 14 5% prevalence of RLS in hemodialysis patients was lower than that has been reported previously The variability in RLS prevalence rates among hemodialysis patients may result from some racial, regional, socioeconomic, or ethnic differences These findings need to be confirmed in larger studies
Renal Involvement in Brucella Infection
(Elsevier Science inc, 2009) Ceylan, Kadir; Karahocagil, Mustafa Kasim; Soyoral, Yasemin; Sayarlioglu, Hayriye; Karsen, Hasan; Dogan, Ekrem; Erkoc, Reha
OBJECTIVES To examine our patients with brucellosis and renal involvement. Although brucellae have been recovered from the urine of patients with brucellosis, renal involvement is uncommon. METHODS The data from 15 patients (8 males and 7 females, mean age 43 +/- 18.9 years, range 16 to 80), who had been admitted to our hospital with the diagnosis of brucellosis with renal involvement from 1998 to 2006, were retrospectively evaluated. RESULTS In almost all cases, urinalysis revealed hematuria and variable amounts of proteinuria; some of the patients had pyuria. Of the 15 patients, 14 had renal failure. The etiology of renal failure was prerenal azotemia in 1, acute tubular necrosis because of nonsteroidal anti-inflammatory drug use in 1, anuric tubulointerstitial nephritis due to rifampin use in 1, nephritis accompanied by brucellar endocarditis in 3, brucellar endocarditis and tubulointerstitial nephritis-associated vasculitis in 1, brucellar membranoproliferative glomerulonephritis in 1, and brucellar tubulointerstitial nephritis clinically in 6 patients. Hemodialysis was required in 5 patients. Chronic renal failure developed in 1 patient, 2 patients were lost to follow-up, and renal function completely recovered in 11 patients. Two patients underwent renal biopsy and membranoproliferative glomerulonephritis with intraglomerular infiltration of histiocytes was identified in 1 patient and chronic tubulointerstitial nephritis associated with vasculitis and immune complex nephritis features was identified in the other. CONCLUSIONS In areas endemic for brucellosis, this infection can be associated with hematuria, proteinuria, and renal failure. In addition, many diverse etiologies can play a role in the renal involvement associated with Brucella infection. UROLOGY 73: 1179-1183, 2009. (C) 2009 Elsevier Inc.
Successful Management of Membranoproliferative Glomerulonephritis Type I in Pregnancy
(Springer Heidelberg, 2010) Kurdoglu, Mertihan; Kurdoglu, Zehra; Adali, Ertan; Soyoral, Yasemin; Erkoc, Reha
We report the successful management of a pregnancy with preexisting nephrotic syndrome due to biopsy-proven primary membranoproliferative glomerulonephritis type I. A 21-year-old Turkish woman with membranoproliferative glomerulonephritis type I was followed up by the obstetrics and gynecology, and nephrology departments of a university hospital throughout her pregnancy starting from the 25th week of gestation. Due to progression of intrauterine growth retardation and fetal distress, a cesarean section was performed in the 33rd week of gestation. Although creatinine was unchanged, proteinuria increased with relatively stable albumin levels 3 months after delivery and her treatment was adjusted accordingly. If the mother is not suffering from hypertension or renal insufficiency, specific therapy for membranoproliferative glomerulonephritis type I during pregnancy provided by a nephrologist together with regular obstetric care may allow the patient to have a viable fetus, which might be growth retarded if proteinuria is increased.
Successful Treatment of Nephrotic Syndrome Due To Fmf Amyloidosis With Azathioprine: Report of Three Turkish Cases
(Springer Heidelberg, 2006) Sayarlioglu, Hayriye; Erkoc, Reba; Sayarliogin, Mehmet; Dogan, Ekrem; Soyoral, Yasemin
Secondary amyloidosis is a well-known complication of certain familial Mediterranean fever (FMF). We presented three Turkish patients with FMF and biopsy proven amyloidosis. These patients were treated with colchicine 1.5 mg/day. They have experienced five to six peritonitis attacks with fever within 1 year. On admission, the laboratory test results were as follows: serum creatinine 2.3, 0.6, and 0.5 mg/dl; albumin 4.2, 1.9, and 1.8 g/dl; and urinary protein excretion 4, 15, and 10 g/day, respectively. All the patients were started azathioprine (AZA) 100 mg/day and attacks were completely stopped. Laboratory findings were as follows after I year of AZA treatment: serum creatinine 1, 0.8, and 0.6 mg/dl; albumin 4.3, 3, and 3.5 g/dl; and urinary protein excretion 3, 8, and 1.5 g/day, respectively. Treatment with azathioprine in addition to colchicine could ameliorate the nephrotic syndrome and control the attacks very effectively in these cases.
Tübülointerstisyel Nefrit ve Üveit Sendromu: Nadir Görülen Bir Olgu Sunumu
(2019) Tekin, Serek; Batur, Muhammed; Seven, Erbil; Soyoral, Yasemin; Altaş, Ahmet Serkan
Tübülointerstisyel nefrit ve üveit (TINU) sendromu, akut tübülointerstisyel nefrit (TIN)’innadir görülen bir alt kümesidir. Genellikle benign seyirli TIN ve relapslar ile birlikte seyreden üveitkliniği ile karakterize bir sendromdur. Üveit tübülointerstisyel nefritten önce oluşabilmekte veyarenal semptomlar hastanın farkında olmadığı kadar hafif düzeyde olabilmektedir. Bu nedenle, oftalmolojik değerlendirme TINU sendromlu hastaların erken tanısında önemli bir rol oynamaktadır.TIN kendi kendini sınırlama eğilimi gösterirken, üveit nüksleri ilk üveit atağından daha şiddetliolma eğilimindedir. Bu nedenle hasta dikkatlice muayene edilmelidir. Tedavisinin daha uzun süreli olması ve sistemik steroid tedavisinden yarar görmesi nedeni ile dirençli üveit olgularında mutlaka ayırıcı tanılar içinde yer almalıdır. Bu çalışmada, TIN sonrasında ortaya çıkan üveit tablosu iletanımladığımız 67 yaşındaki TINU sendromlu kadın olguya, kortikosteroid tedavisi başlandı. Tedavisonrası takip eden bir yıl boyunca böbrek fonksiyon testleri normal aralıkta seyretti ve bu süre boyunca üveit atağı izlenmedi. Bu süre zarfında olgunun her iki gözüne katarakt ameliyatı yapıldı veherhangi bir komplikasyon gözlenmedi.